Program
Timolol
Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.
Drug pageTimolol: every studyMany companies study it; this page follows only the 23 they lead. All 84 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 80 open or running | phase 4since Aug 13, 2008 | Aug 13, 2008 | none ahead |
| Merckits history only | 30 open or running | phase 3since Apr 12, 2005 | Apr 12, 2005 | none ahead |
| Santen Pharmaceuticalits history only | 30 open or running | phase 3since Feb 28, 2011 | Apr 7, 2009 | none ahead |
| Viatrisits history only | 30 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Auson Pharmaceuticals | 20 open or running | phase 3since Oct 29, 2024 | Oct 29, 2024 | none ahead |
| Credit Valley EyeCareits history only | 10 open or running | phase 4since Feb 13, 2012 | Feb 13, 2012 | none ahead |
| Glaukosits history only | 10 open or running | phase 4since Jun 1, 2009 | Jun 1, 2009 | none ahead |
| Laboratorios Poenits history only | 10 open or running | phase 4since Mar 30, 2023 | Mar 30, 2023 | none ahead |
| Vistakon Pharmaceuticalsits history only | 10 open or running | phase 4since Dec 5, 2008 | Dec 5, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Auson Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2024First study: phase 3 study in Hemangioma, CapillaryFirst studyNCT06677853 · 168 enrolled · China
- Jan 23, 2025Phase 1 study in Healthy SubjectsNCT06824948 · 28 enrolled · China
TargetBeta
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 2 Auson Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06824948Healthy Subjects · China | 1 | Completed | Dec 12, 2018 | 28 |
| NCT06677853Hemangioma, Capillary · China | 3 | Completed | Jun 21, 2022 | 168 |
How it is read
Names in the registry
- “Timolol Maleate Gel”, 4 entries
- “Timolol”, 3 entries
- “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
- “timolol 0.5%”, 2 entries
- “timolol maleate”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 14 studies
- Glaucoma, 9 studies
- Hemangioma, Capillary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.